Clinical trials: Tumours, Gynecological
Solid Tumors
Study of INCB123667 in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with…
- Trial name
- NCT05238922
- Testing
- INCB0123667, Palbociclib, Bevacizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 291 people
- Sponsor
- Incyte Corporation
Ovarian Cancer, Clear Cell Carcinoma
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
- Conditions
- Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma
- Trial name
- NCT05032040
- Testing
- vudalimab
- Where
- 17 sites in United States
- Volunteers
- 170 people
- Sponsor
- Xencor, Inc.
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT05379985
- Testing
- RMC-6236
- Where
- 21 sites in United States
- Volunteers
- 754 people
- Sponsor
- Revolution Medicines, Inc.
Adult, Gynecological Tumors
Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)
This study is an early exploration clinical study with one arm. The study consists of two stages, namely the dose escalation stage and the dose extension stage:
- Trial name
- NCT06191900
- Testing
- Autologous tumor infiltrating lymphocyte injection（GT201）
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Grit Biotechnology
Ovarian Neoplasms
Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.
ANGLE has developed the Parsortix™ Cell Separation System (Parsortix), an automated system capable of harvesting rare circulating cells for analysis from a sample of peripheral blood based on cellular size and deformability.
- Trial name
- EMBER (NCT02781272)
- Testing
- Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Angle plc
Gynecological Malignancies, Genital Neoplasms, Female
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in gynecological cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia…
- Conditions
- Gynecological Malignancies, Genital Neoplasms, Female, Anemia
- Trial name
- NCT00121030
- Testing
- darbepoetin alfa, recombinant human erythropoietin (rHuEPO)
- Sponsor
- Amgen
Advanced Gynecological Malignancies
Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies
This study is a single-arm, open-label, multicenter Phase IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of BRY812 for Injection in patients with LIV-1-positive advanced gynecological…
- Trial name
- NCT07311538
- Testing
- BRY812 for injection
- Volunteers
- 56 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Myomas, Ovary Cysts
The Efficacy and Safety Study of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Peritoneal Adhesions
The purpose of this study was to determine whether the new crosslinked hyaluronan hydrogel was safe to use, and was effective for the prevention/reduction of adhesion formation following gynecological surgery
- Conditions
- Myomas, Ovary Cysts, Endometriotic Cysts, Adhesions
- Trial name
- BAP (NCT02166554)
- Testing
- Saline, Cross-linked Hyaluronan Hydrogel
- Where
- 7 sites in China
- Volunteers
- 216 people
- Sponsor
- BioRegen Biomedical (Changzhou) Co., Ltd
Gynecological Malignancies, Solid Tumors
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid Tumors
This study is a single-arm, open-label, multicenter, non-randomized phase II clinical study evaluating the efficacy and safety of BL-M09D1 for injection in patients with locally advanced or metastatic gynecological malignancies…
- Trial name
- NCT07769229
- Testing
- BL-M09D1
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Solid Tumor
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.
- Trial name
- NCT01607905
- Testing
- Selinexor, Acetaminophen
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 192 people
- Sponsor
- Karyopharm Therapeutics Inc
Ovarian Neoplasms
Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.
ANGLE has developed the Parsortix™ Cell Separation System (Parsortix), an automated system capable of harvesting rare circulating cells for analysis from a sample of peripheral blood based on cellular size and deformability.
- Trial name
- NCT02785731
- Testing
- Pelvic imaging, Blood draw, laparotomy or laparoscopy
- Where
- 5 sites in Austria, Germany
- Volunteers
- 204 people
- Sponsor
- Angle plc
Cancer, Carcinoma
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
This study is a 2 part, 2 cohort, open-label, dose escalation/de escalation study of AMG 386 in combination with either pegylated liposomal doxorubicin or topotecan in subjects with recurrent ovarian cancer.
- Conditions
- Cancer, Carcinoma, Fallopian Tube Cancer, Gynecological Malignancies
- Trial name
- NCT00770536
- Testing
- A1: AMG 386 10 mg/kg + Liposomal doxorubicin, A3: AMG 386 15mg/kg + Liposomal doxorubicin, B1: AMG 386 10 mg/kg + Topotecan
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 103 people
- Sponsor
- Amgen
Ovarian Cancer, Endometrial Cancer
Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors
The purpose of this study is to determine whether AEZS-108 shows anti-tumor activity and is tolerated in patients with gynecological tumors (ovarian / endometrial cancer) that have been shown to express receptors for the…
- Trial name
- NCT00569257
- Testing
- AEZS-108
- Where
- 17 sites in Bulgaria, Germany
- Volunteers
- 85 people
- Sponsor
- AEterna Zentaris
Adult Gynecological Tumors
Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors
This study is an early exploration clinical study with one arm. The study consists of two stages, namely the dose escalation stage and the dose extension stage:
- Trial name
- NCT06834542
- Testing
- Autologous tumor infiltrating lymphocyte injection（GT201）
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Grit Biotechnology
Ovarian Cancer
A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable
This randomized, open-label study will evaluate the efficacy and safety of neoadjuvant bevacizumab in participants with initially unresectable, FIGO stage IIIC/IV ovarian, tubal, or peritoneal cancer.
- Trial name
- ANTHALYA (NCT01739218)
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 15 sites in France
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche
Cervical Cancer, Ovarian Cancer
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic cervical cancer or ovarian cancer failed or…
- Trial name
- NCT06769152
- Testing
- HLX43
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Shanghai Henlius Biotech
Hereditary Cancer
Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes
A prospective, non-interventional study to evaluate the impact of a process engineering intervention on screening and testing outcomes for common hereditary cancer syndromes in community-based OB/GYN settings.
- Trial name
- NCT03081455
- Testing
- Diagnostic Test
- Where
- 2 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Myriad Genetic Laboratories, Inc.
Gynecological Tumors, Solid Tumors
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid Tumors
This Phase Ib/II study is a clinical study to explore the efficacy and safety of BL-M08D1 for injection in patients with recurrent or metastatic gynecological tumors and other solid tumors.
- Trial name
- NCT07793825
- Testing
- BL-M08D1
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Gynecologic Malignancies
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Advanced Gynecological Tumors.
This is a multicenter, open-label, phase II clinical study to evaluate the safety and preliminary efficacy of RNK08954 in patients with advanced gynecological tumors
- Trial name
- NCT07848893
- Testing
- RNK08954
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Ranok Therapuetics Co. Ltd.
Ovarian Cancer, Fallopian Tube Cancer
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Part 1 (Completed Enrollment) - The purpose of the first part of the study was to evaluate the safety of different doses and dosing regimens of oral rucaparib administered daily to patients with solid tumors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
- Trial name
- NCT01482715
- Testing
- Rucaparib
- Where
- 16 sites in United States, Canada and 3 more
- Volunteers
- 136 people
- Sponsor
- pharmaand GmbH